OREANDA-NEWS. The European Medicines Agency (EMA) will send a team of experts to Russia in April to review clinical trials and the production of the Russian Sputnik V coronavirus vaccine. This was announced by the head of the department of health threats and vaccination strategy of the agency, Marco Cavaleri.

According to him, in addition to Sputnik V, two more manufacturers of anti-coronavirus drugs, the German Curevac and the American Novavax, are currently being tested by the European medical authorities.

Cavaleri said on the Italian TV Rai3: “Sputnik V is undergoing a cyclical check, so we will consider all the data when it is collected in order to more quickly authorize the Russian vaccine. In April, we will conduct an inspection in Russia in terms of production and clinical trials. Then we will try to understand by what time we will have all the data necessary for the possible approval of this vaccine in the end. "

Earlier, the chairman of the working group on coronavirus reported that the EMA could approve the Russian drug no earlier than May 2021.

The Sputnik V vaccine has been approved in 52 countries with a total population of over 1.4 billion people. Sputnik V ranks second in the world in terms of the number of approvals received by government regulators.